Johan Vekemans

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Efficacy of RTS,S/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5–17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial”.

Efficacy of RTS,S/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5–17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial

The Lancet Infectious Diseases(2022)10.1016/s1473-3099(22)00273-0

N/A

2.6DataRank · unranked

72 citations

Daniel Ansong, Simon Kariuki, Samuel Adjei, Anne Bollaerts, Christian F. Ockenhouse +35 more

Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial

Frontiers in Immunology(2021)10.3389/fimmu.2021.694759

N/A

1.2DataRank · unranked

42 citations

Ruth Payne, Iona J. Taylor, Kazutoyo Miura, Carol A. Long, Sean C. Elias +23 more

Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate

New England Journal of Medicine(2025)10.1056/nejmoa2501073

N/A

0.450DataRank · unranked

13 citations

Marija Zaric, Mark Kieh, Lindsey R. Baden, David Fitzpatrick, Arianna Marini +38 more

Clinical trials of tuberculosis vaccines in the era of increased access to preventive antibiotic treatment

The Lancet Respiratory Medicine(2023)10.1016/s2213-2600(23)00084-x

N/A

0DataRank · unranked

8 citations

Mike Frick, Gavin Churchyard, Alberto L. García‐Basteiro, Mark Hatherill, Willem A. Hanekom +7 more

Measuring indirect transmission-reducing effects in tuberculosis vaccine efficacy trials: why and how?

The Lancet Microbe(2023)10.1016/s2666-5247(23)00112-x

N/A

0DataRank · unranked

4 citations

Gavin Churchyard, Frank Cobelens, Willem A. Hanekom, Philip C. Hill, Benjamin A. Lopman +8 more

What is next for BCG revaccination to prevent tuberculosis?

The Lancet Respiratory Medicine(2024)10.1016/s2213-2600(24)00009-2

N/A

0DataRank · unranked

2 citations

Andrew Fioré-Gartland, Willem A. Hanekom, Johan Vekemans, Alberto L. García‐Basteiro, Gavin Churchyard +6 more